Good morning from the Financial Times.

Today is Tuesday, February 10th, and this is your FT News Briefing.

Looks like the political turmoil in the UK has mellowed out, and Novo Nordisk is hitting back at copycat drugs.

Plus, is American bank deposit insurance still strong enough?

The Silicon Valley Bank failure was the first one to really take place in a fully digital era.

And that meant that money could just move so much faster than it ever had before.

I'm Sonia Hudson, and here's the news you need to start your day.

Thank you. need to start your day. UK government bonds went on a wild ride yesterday.

Yields on the tenure jumped almost a tenth of a percentage point in the morning.

Guilt investors were worried about more political fallout for Prime Minister

Kier Starmer. He's come under fire for appointing Peter Mandelson as U.S. ambassador, even though he

knew about Mandelson's ongoing relationship with Jeffrey Epstein. On Monday morning, Scottish

labor leader Anna Sarwa called for Starmer to step down.

Investors worried that Starmer's potential downfall could lead to a rise in borrowing under a new prime minister. But his cabinet members swooped in and voiced their support for him. That seemed

to calm traders and guilt recovered some of their earlier losses. Several labor MPs told the

F.T. that Starmor's position is safe for now, but local elections in May will be a big test

for him.

Novo Nordisk is suing to stop a U.S. telehealth company from selling copycat versions of its weight loss drugs.

The move escalates an industry-wide battle over obesity medications, and it comes as Novo is trying to reassure its investors.

The Danish company's share price has fallen about 15% over the past week,

but it bounced back a little yesterday after the lawsuit news broke. Here to tell us more is

the FT's U.S. pharmaceutical correspondent, Patrick Temple West. Hey, Patrick. Hello, Sonia.

...